At the time of writing, Dyne Therapeutics Inc [DYN] stock is trading at $14.05, down -4.29%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The DYN shares have gain 7.58% over the last week, with a monthly amount glided 6.64%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Dyne Therapeutics Inc [NASDAQ: DYN] stock has seen the most recent analyst activity on October 10, 2025, when Oppenheimer downgraded its rating to a Perform. Previously, Raymond James upgraded its rating to Strong Buy on August 25, 2025, and kept the price target unchanged to $35. On June 24, 2025, Bernstein initiated with a Mkt Perform rating and assigned a price target of $13 on the stock. Evercore ISI started tracking with a Outperform rating for this stock on May 29, 2025, and assigned it a price target of $46. In a note dated March 12, 2025, BMO Capital Markets initiated an Outperform rating and provided a target price of $50 on this stock.
For the past year, the stock price of Dyne Therapeutics Inc fluctuated between $6.36 and $35.90. Currently, Wall Street analysts expect the stock to reach $24 within the next 12 months. Dyne Therapeutics Inc [NASDAQ: DYN] shares were valued at $14.05 at the most recent close of the market. An investor can expect a potential return of 70.82% based on the average DYN price forecast.
Analyzing the DYN fundamentals
Gross Profit Margin for this corporation currently stands at -0.39% with Operating Profit Margin at -280.49%, Pretax Profit Margin comes in at -262.65%, and Net Profit Margin reading is -262.65%. To continue investigating profitability, this company’s Return on Assets is posted at -0.57, Equity is -0.64 and Total Capital is -0.64. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Dyne Therapeutics Inc [NASDAQ:DYN] has a current ratio of 16.83. Also, the Quick Ratio is 16.83, while the Cash Ratio stands at 11.7.
Transactions by insiders
Recent insider trading involved Cox John, CEO & President, that happened on Sep 05 ’25 when 2640.0 shares were sold. Chief Commercial Officer, Friedl-Naderer Johanna completed a deal on Sep 04 ’25 to sell 894.0 shares. Meanwhile, Chief Commercial Officer Friedl-Naderer Johanna sold 144.0 shares on Sep 05 ’25.
